Co-Diagnostics Inc (CODX)
NASDAQ:CODX
Earnings Data
Report Date
May 07, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.24Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call conveyed clear strategic and operational progress — NASDAQ relisting, CoSara manufacturing license and regional expansion, CoMira JV advancement, strengthened IP, progress in clinical programs (1,200+ enrollments) and AI development — but these positives are offset by significant financial headwinds: an ~84.6% revenue decline driven by lower grant income, a large $18.9M noncash impairment that increased operating expenses, a widened GAAP net loss ($46.9M) and a ~60% reduction in cash to $11.9M. Management highlighted cost discipline and improved adjusted EBITDA excluding impairment, and articulated near-term commercialization paths (notably TB in India expected by Q3 2026), yet the company faces continued cash burn and will need to secure additional financing or strategic transactions to execute growth plans. Overall, the call signals meaningful operational milestones but material financial and execution risks remain.Company Guidance
NASDAQ Relisting and Corporate Stability
Successfully completed appeal and had shares relisted on NASDAQ, removing a significant listing overhang and allowing management to refocus on execution and commercialization.
CoSara India: Manufacturing License and Regional Expansion
CoSara received CDSCO license to manufacture the PCR Pro instrument in India, preparing local production of instrument and consumables; commercial/distribution territory expanded to Bangladesh, Pakistan, Nepal and Sri Lanka, increasing addressable market from about $11B to ~$13B.
TB Opportunity and WHO Alignment
Preparing TB clinical performance studies in India where TB burden is highest; WHO updated guidance favoring near point-of-care molecular TB tests and tongue swab sampling — tests designed for SARS platform are aligned with this guidance; preclinical third-party studies showed performance comparable to or exceeding other molecular TB tests; management expects TB commercialization in India by Q3 2026.
CoMira Joint Venture Progress in MENA
CoMira JV with Arabian Eagle progressing toward local manufacturing in Saudi Arabia with lease finalization and operational readiness across Saudi and 18 additional MENA markets; expected to be first domestic manufacturer of molecular diagnostics in the Kingdom, strengthening regional positioning.
Clinical Pipeline and Trial Enrollment
Upper respiratory multiplex clinical program progressing with enrollment in ~8 U.S. locations; management reported in excess of 1,200 patients already enrolled and will move forward with an initial FDA submission focusing on flu A, flu B and RSV to accelerate timelines while keeping option to add COVID later.
Intellectual Property Strengthening
Received international patent grants covering core components of the Co-Dx PCR platform, including grants in Australia and Japan, bolstering IP protection ahead of commercialization and international expansion.
AI Platform Expansion
Expanding Co-Dx primer AI platform to support assay design, result interpretation and predictive insights; multiple AI models already in place, representing a longer-term revenue/efficiency opportunity.
Cost Discipline and Adjusted EBITDA Improvement (Excluding Impairment)
Excluding a noncash impairment, operating expenses declined year-over-year (R&D down 9.1% to $19.1M, sales & marketing down 46.7% to $2.4M, G&A down 43.8% to $9.1M) and Adjusted EBITDA improved to a loss of $28.0M from a loss of $33.5M (improvement of ~$5.5M, ~16.4%).
CODX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CODX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 31, 2026 | $1.86 | $1.62 | -12.90% |
Nov 13, 2025 | $11.16 | $9.94 | -10.94% |
Aug 14, 2025 | $7.96 | $8.83 | +10.85% |
May 08, 2025 | $10.66 | $10.20 | -4.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Co-Diagnostics Inc (CODX) report earnings?
Co-Diagnostics Inc (CODX) is schdueled to report earning on May 07, 2026, Before Open (Confirmed).
What is Co-Diagnostics Inc (CODX) earnings time?
Co-Diagnostics Inc (CODX) earnings time is at May 07, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CODX EPS forecast?
Currently, no data Available